---
document_datetime: 2023-09-21 17:40:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/kengrexal-epar-all-authorised-presentations_en.pdf
document_name: kengrexal-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6358897
conversion_datetime: 2025-12-15 02:31:47.386112
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical form                                        | Route of administration   | Immediate Packaging   | Pack size   |
|-----------------|-----------------|------------|------------------------------------------------------------|---------------------------|-----------------------|-------------|
| EU/1/15/994/001 | Kengrexal       | 50 mg      | Powder for concentrate for solution for injection infusion | Intravenous use           | Vial (glass)          | 10 vials    |